Logo image of BSX

BOSTON SCIENTIFIC CORP (BSX) Stock Fundamental Analysis

USA - NYSE:BSX - US1011371077 - Common Stock

97.3 USD
+1.06 (+1.1%)
Last: 10/15/2025, 2:50:07 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to BSX. BSX was compared to 191 industry peers in the Health Care Equipment & Supplies industry. BSX scores excellent on profitability, but there are some minor concerns on its financial health. BSX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, BSX could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

BSX had positive earnings in the past year.
In the past year BSX had a positive cash flow from operations.
BSX had positive earnings in 4 of the past 5 years.
BSX had a positive operating cash flow in each of the past 5 years.
BSX Yearly Net Income VS EBIT VS OCF VS FCFBSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

Looking at the Return On Assets, with a value of 6.03%, BSX belongs to the top of the industry, outperforming 83.77% of the companies in the same industry.
BSX's Return On Equity of 11.17% is amongst the best of the industry. BSX outperforms 87.43% of its industry peers.
BSX's Return On Invested Capital of 7.66% is amongst the best of the industry. BSX outperforms 84.29% of its industry peers.
BSX had an Average Return On Invested Capital over the past 3 years of 6.54%. This is below the industry average of 8.89%.
The 3 year average ROIC (6.54%) for BSX is below the current ROIC(7.66%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.03%
ROE 11.17%
ROIC 7.66%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
BSX Yearly ROA, ROE, ROICBSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

BSX has a Profit Margin of 13.54%. This is amongst the best in the industry. BSX outperforms 91.10% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
BSX has a Operating Margin of 18.69%. This is amongst the best in the industry. BSX outperforms 90.05% of its industry peers.
In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
The Gross Margin of BSX (68.30%) is better than 75.39% of its industry peers.
BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.69%
PM (TTM) 13.54%
GM 68.3%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
BSX Yearly Profit, Operating, Gross MarginsBSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
BSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BSX has been increased compared to 5 years ago.
The debt/assets ratio for BSX is higher compared to a year ago.
BSX Yearly Shares OutstandingBSX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
BSX Yearly Total Debt VS Total AssetsBSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

An Altman-Z score of 5.38 indicates that BSX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.38, BSX belongs to the top of the industry, outperforming 81.68% of the companies in the same industry.
The Debt to FCF ratio of BSX is 3.33, which is a good value as it means it would take BSX, 3.33 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.33, BSX belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
BSX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
BSX has a Debt to Equity ratio (0.50) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.33
Altman-Z 5.38
ROIC/WACC0.93
WACC8.26%
BSX Yearly LT Debt VS Equity VS FCFBSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

BSX has a Current Ratio of 1.37. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
BSX has a worse Current ratio (1.37) than 78.01% of its industry peers.
A Quick Ratio of 0.82 indicates that BSX may have some problems paying its short term obligations.
BSX has a worse Quick ratio (0.82) than 83.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 0.82
BSX Yearly Current Assets VS Current LiabilitesBSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

8

3. Growth

3.1 Past

BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.91%, which is quite impressive.
Measured over the past years, BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
Looking at the last year, BSX shows a very strong growth in Revenue. The Revenue has grown by 21.45%.
Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 9.30% on average per year.
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%

3.2 Future

BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.40% yearly.
BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.12% yearly.
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BSX Yearly Revenue VS EstimatesBSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B
BSX Yearly EPS VS EstimatesBSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4 5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 34.38, the valuation of BSX can be described as expensive.
71.73% of the companies in the same industry are more expensive than BSX, based on the Price/Earnings ratio.
BSX's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.49.
With a Price/Forward Earnings ratio of 28.35, BSX can be considered very expensive at the moment.
73.30% of the companies in the same industry are more expensive than BSX, based on the Price/Forward Earnings ratio.
BSX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.99.
Industry RankSector Rank
PE 34.38
Fwd PE 28.35
BSX Price Earnings VS Forward Price EarningsBSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

BSX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BSX is cheaper than 70.68% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BSX is valued a bit cheaper than the industry average as 77.49% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 41.38
EV/EBITDA 32.2
BSX Per share dataBSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 15.51% in the coming years.
PEG (NY)1.72
PEG (5Y)3.6
EPS Next 2Y16.93%
EPS Next 3Y15.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BSX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOSTON SCIENTIFIC CORP

NYSE:BSX (10/15/2025, 2:50:07 PM)

97.3

+1.06 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-23 2025-07-23/bmo
Earnings (Next)10-22 2025-10-22/bmo
Inst Owners93.27%
Inst Owner Change-0.28%
Ins Owners0.15%
Ins Owner Change-1.6%
Market Cap144.17B
Analysts86.34
Price Target126.25 (29.75%)
Short Float %1.29%
Short Ratio2.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)0.2%
PT rev (3m)4.27%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)2.21%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)2.04%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)2.02%
Valuation
Industry RankSector Rank
PE 34.38
Fwd PE 28.35
P/S 7.8
P/FCF 41.38
P/OCF 33.65
P/B 6.43
P/tB N/A
EV/EBITDA 32.2
EPS(TTM)2.83
EY2.91%
EPS(NY)3.43
Fwd EY3.53%
FCF(TTM)2.35
FCFY2.42%
OCF(TTM)2.89
OCFY2.97%
SpS12.48
BVpS15.13
TBVpS-1.97
PEG (NY)1.72
PEG (5Y)3.6
Profitability
Industry RankSector Rank
ROA 6.03%
ROE 11.17%
ROCE 9.51%
ROIC 7.66%
ROICexc 7.77%
ROICexgc 26.52%
OM 18.69%
PM (TTM) 13.54%
GM 68.3%
FCFM 18.84%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexcg growth 3Y8.56%
ROICexcg growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.33
Debt/EBITDA 2.33
Cap/Depr 60.84%
Cap/Sales 4.33%
Interest Coverage 250
Cash Conversion 89.77%
Profit Quality 139.08%
Current Ratio 1.37
Quick Ratio 0.82
Altman-Z 5.38
F-Score5
WACC8.26%
ROIC/WACC0.93
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.06%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%